PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial
Clinical Trial Progress
PYC Therapeutics has received approval from the Safety Review Committee to escalate the dosing of its investigational drug, PYC-001, from cohort 2 to cohort 3 in the clinical trial for Autosomal Dominant Optic Atrophy (ADOA).
Future Development Plans
The company will continue to generate safety and efficacy data through 2025 and plans to initiate a Multiple Ascending Dose (MAD) study and Open-Label Extension (OLE) study following the single ascending dose phase. Successful completion of these studies will lead to a Phase 2/3 trial aimed at supporting a New Drug Application.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
